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Abstract
Background: Tumor necrosis factor-α (TNF-α) is an important inflammatory factor produced by activated
macrophages and monocytes and plays an important role in the pathogenesis of diabetic peripheral neuropathy
(DPN). To evaluate the effect of TNF-α signaling suppression and the potential of TNF-α in the treatment of DPN, a
recombinant human TNF-α receptor-antibody fusion protein (rhTNFR:Fc) was used. We focused on the
pathophysiology of the sciatic nerve and examined the expression of myelin basic protein (MBP) under DPN status
with or without TNF-α inhibition.
Methods: The DPN rat model was generated by intraperitoneal injection of streptozotocin and by feeding with a
high-fat, high-sugar diet. The nerve conduction velocity (NCV) in sciatic nerve of rat was monitored over a period of
four weeks. The histopathological changes in nerve tissue were examined through traditional tissue histology and
ultrastructure transmission electron microscopy (TEM). The expression of MBP was examined through western blot
analysis.
Results: The DPN induced rats showed significant signs of nerve damage including lower NCV, demyelination of
nerve fibers, disorganization of lamellar and axonal structures, and decreased expression of MBP in the nerve tissue.
The inhibition of TNF-α in the DPN rats resulted in a significant recovery from those symptoms compared to the
DPN rats.
Conclusions: Our study demonstrates that TNF-α plays a key role in the pathogenesis of DPN and its inhibition by
rhTNFR:Fc can prove to be a useful therapeutic strategy for the treatment of and/or prevention from DPN
symptoms.
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Background
Diabetic peripheral neuropathy (DPN) is a severe long-
term complication of diabetes affecting about 50% dia-
betic patients [1,2]. It is a condition associated with
progressive degeneration of nerve fibers [3] and has be-
come a growing concern of researchers and clinicians
due to increased prevalence and vague etiology. Over
many years, the treatment of type 2 diabetes has been
around the high blood sugar (glucose) toxicity. Even
though blood sugar and blood pressure in many patients
can be controlled, the development of DPN is neither
preventable nor controlled. Studies have shown that the
immune damage during the occurrence of type 2 dia-
betes may play a role in the development of DPN [4].
Recent evidences are being accumulated favoring the as-
sociation between inflammation and type 2 diabetes, in-
cluding its related complications like DPN [5,6]. Tumor
necrosis factor-α (TNF-α) has been shown to play a central
role in the pathogenesis of DPN [7]. Elevated levels of
TNF-α and soluble TNF-α receptors (sTNFR1 and
sTNFR2) have been reported in the serum of patients with
DPN [8-10].
In this study, we used the previously described rat
model of DPN [11], where DPN pathology was induced
by streptozotocin administration, to evaluate the effect
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TNF-α receptor-antibody fusion protein. In order to in-
vestigate the beneficial effect of TNF-α inhibition on
DPN, we focused on the pathophysiology of the sciatic
nerve and measured the nerve conduction. The ultra-
structure of the sciatic nerve and the expression of
myelin basic protein (MBP) under DPN status with or
without TNF-α inhibition were also examined.
Materials and methods
Reagents
Recombinant human tumor necrosis factor-α receptor
II:IgG Fc fusion protein (rhTNFR:Fc) was obtained from
Shanghai CP Guojian Pharmaceutical Co., Ltd (Shanghai,
China). Rabbit anti-MBP monoclonal antibody was pur-
chased from Sigma (St. Louis, MO, USA). HRP-conjugated
goat anti-rabbit secondary antibody was purchased from
Beijing Zhongshan Biotechnology Co., Ltd (Beijing, China).
Experimental animals
Forty eight male Wistar rats (140 to 160 g weight, 6 weeks
old) were purchased from Shanghai Animal Center,
Medical College of Fudan University and housed in the
animal facility for at least 5 days before use. All animal
experiments were approved by the Ethic Committee of
Animal Care of the Jinshan Hospital (# 2011-03)
according to the Guidelines for Animal Experiments of
the Chinese Academy of Medical Sciences. These ani-
mals were randomly divided into four groups (12 each):
normal control, DPN, DNP plus low dose of rhTNFR:Fc
(0.4 mg/kg, referred to as the DPN + T1), and DNP plus
high dose of rhTNFR:Fc group (4 mg/kg, referred to as
the DPN + T2). Animals were injected subcutaneously
with rhTNFR:Fc in rhTNFR:Fc groups or with physiological
buffered saline (PBS) as a vehicle in normal control and
DPN groups twice per week for 4 weeks.
Generation of diabetic peripheral neuropathy rats
The rat model of DPN was generated as previously de-
scribed [11] with a slight modification. Briefly, the ani-
mals were fed with a high-fat, high-sugar diet (normal
diet mixed with 10% lard and 20% sucrose) for 6 weeks.
Diabetes was then induced by intraperitoneal injection
of a single dose of streptozotocin (STZ, Sigma) at 30
mg/kg body weight in 0.1 M citrate buffer (pH 4.1). Dia-
betic animals were validated with the detection of high
blood glucose level (>16.7 mmol/L), 48 hours after the
STZ administration. Vehicle control animals were injected
with the citrate buffer only. Following injection of STZ,
the diabetic animals were continuously fed with a high-fat,
high-sugar diet for another 4 weeks to generate DPN ani-
mals. The DPN model was validated by the lowering of
nerve conduction velocity (NCV, <40 m/s). We monitored
blood glucose levels during the experiment. One micro-
liter of blood from the tail vein was used for measuring
the level of blood glucose by the Fast Blood Glucose Moni-
toring System (Breeze 2, Bayer Healthcare, Mishawaka, IN,
USA).
Measurement of nerve conduction velocity
NCV was measured in the sciatic nerve. Briefly, rats
were anesthetized by peritoneal injection with 10%
chloral hydrate (0.3 ml/100 g) and fixed on a board.
After disinfection of the proximal and distal ends of
lower limb with alcohol, the electrodes were placed. For
the determination of motor nerve conduction velocity
(MNCV), the sciatic nerve was stimulated with single
supramaximal square wave pulses (5 to 10 Ma and 40 μs
duration) via fine needle electrodes inserted percutan-
eously in the sciatic notch and the ankle. The distance
between the two sites of stimulation was 2 mm. MNCV
was calculated by subtracting the distal latency from the
proximal latency, and the result was divided into the dis-
tance between the stimulating and recording electrode.
Sensory nerve conduction velocity (SNCV) was mea-
sured and recorded. The site of stimulation was located
in the ankle and the recording site was in the sciatic
notch. The maximal SNCV was calculated by measuring
the latency to the onset/peak of the initial negative de-
flection and the distance between stimulating and re-
cording electrodes, and the result was divided by latency
period. All measurements were made in triplicate from
each group.
Preparation of sciatic nerve tissue and
immunohistochemical staining
Rat was anesthetized by intraperitoneal injection of 10%
chloral hydrate. The bilateral sciatic nerves were isolated
and 1 cm of sciatic nerve tissue was fixed with 10% for-
maldehyde. The samples were then dehydrated and
embedded in paraffin. After sectioning (5 μm thick) with
a rotary slicer (LEICA RM2135, Wetzlar, Germany),
hematoxylin and eosin stain (H&E) and luxol fast blue
staining was performed to evaluate the neuronal damage
and myelination status. The expression of MBP was ex-
amined by immunohistochemistry. Briefly, the section of
sciatic nerve tissue was rinsed with 0.01 mol/L phos-
phate buffered saline (PBS, pH 7.2 to 7.4) three times, 5
min each, and then incubated with 10% normal rabbit
serum at 37°C for 1 hour to block the non-specific bind-
ing. The sectioned tissue was then incubated with rabbit
anti-rat MBP primary antibody (1:400 dilution, Sigma) at
37°C for 4 hours and subsequently at 4°C for 48 hours.
After three times rinse with PBS, the sectioned tissue
was incubated with horseradish peroxidase-conjugated
goat anti-rabbit secondary antibody (1:2,000 dilution,
Beijing Zhongshan Biotechnology Co., Ltd) at 37°C for 1
hour. After three times wash with PBS, the section was
rinsed with 0.1 mol/L Tris–HCl buffer for 5 min. The
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section was then incubated in 0.05% DAB in 0.05 mol/L
Tris–HCl buffer plus 3% hydrogen peroxide 1 to 2 drops
for 5 to 15 min until the color was changed. The reac-
tion was then stopped by dipping the slide into 0.05
mol/L Tris–HCl buffer. The slides were then dried and
mounted with a cover slip. Rat brain tissue was used for
positive control. For negative control, a normal rabbit
serum (1:400 dilution) was used.
Western blotting
Total protein was extracted from sciatic nerve tissue. Equal
amount protein samples were subjected to SDS-PAGE and
were transferred to PVDF membranes. After blocking with
1% skim milk in TBS-T at room temperature for 1 hour,
the membranes were probed with rabbit anti-rat MBP or
β-actin (1:500 dilution, Sigma) primary antibody at 4°C
overnight and subsequently incubated with horseradish
peroxidase-conjugated goat anti-rabbit secondary antibody
(1:2,000 dilution) at room temperature for 2 hours. Signals
were detected using ECL-Plus (Santa Clara, CA, USA)
and quantified using Bio-Rad2000 gel imaging system
with QUANTITY ONE software (Bio-Rad Laboratories,
Hercules, CA, USA).
Transmission electron microscopy
The sciatic never tissue was isolated as described before
and placed in 2.5% glutaraldehyde. After the sample was
cut into 1 × 1 × 3-4 mm, the nerve was divided into four
parts longitudinally and fixed in 2.5% glutaraldehyde at
4°C overnight. The sciatic nerve tissue was post-fixated
with 1% osmium tetroxide for 1 hour and then embed-
ded in Epon812 resin. The tissue was cut into ultrathin
sections (60 nm) and double stained with uranyl acetate
and lead citrate for 10 min. After dehydration with etha-
nol and acetone, respectively, the samples were exam-
ined under transmission electron microscopy (Philips
CM 120, Royal Dutch Philips Electronics Ltd, Eindhoven,
Netherlands).
Statistical analysis
All statistical analyses were carried out using SigmaStat
(Chicago, IL, USA). Comparisons between groups were
performed using either a paired student t-tests or one-
way analysis of variance (ANOVA), where indicated.
Data were presented as mean ± SEM. Differences were
considered significant at values of P <0.05.
Results
Validation of diabetic peripheral neuropathy rat model
The DPN model was generated by high-fat, high-sugar
diet for 6 weeks, followed by a single dose of STZ injec-
tion. After 48 hours of STZ administration, the DPN
rats were validated by their higher blood glucose levels
as compared with sham animals. We observed the higher
glucose levels in DPN rat than normal control group
(Table 1). However, there was no significant difference
of the levels of blood glucose before (0 week) and after
(4 weeks) the injection of rhTNFR:Fc in each group.
Inhibition of TNF-α partially rescued the decrease of
motor nerve conduction velocity and sensory nerve
conduction velocity in diabetic peripheral neuropathy rat
The DPN status is characterized by the lowering of
MNCV and SNCV. The MNCV and SNCV in different
groups were measured before and after the treatment of
rhTNFR:Fc. We found that animals with DPN had sig-
nificantly lower MNCV and SNCV compared with
control animals (Figure 1A and 1B; both P <0.001, a ver-
sus b), that was further decreased after four weeks.
There was no statistical difference between the low-dose
and high-dose groups, but the MNCV and SNCV values
in the high-dose group (DPN-T2) were significantly higher
than the DPN group of animals (Figure 1A, P <0.01 and
1B, P <0.05).
TNF-α inhibition resulted in attenuation of the
pathological changes of diabetic peripheral neuropathy
To examine the histopathology, H&E staining of rat
sciatic nerve was performed. In the control rats with
normal glucose levels the myelinated nerve fibers were
similar in size. Myelin appeared dense, round and uni-
form with ordered lamellar structure presenting neither
axonal shrinkage nor its swelling. The wall of the
endoneurial capillary was also even (Figure 2A and 2B).
In DPN rats the myelin sheath of the myelinated nerve
fibers was thin, loose, and disorganized and exhibited
vacuolar-like defects (Figure 2C and 2D). Some nerve fi-
bers in sciatic nerve appeared demyelinated. Lamellar
spaces were expanded and separated from each other
and visible signs of axonal atrophy were evident. The
endoneurial capillary displayed thick wall and irregular
lumen. The average cross-sectional area and the density of
myelin nerve fibers was decreased in the DPN group as
compared with the control group, while this decrease was
partially restored in the DPN group treated with high-
dose of rhTNFR:Fc (Figure 2E and 2F). The morphology
Table 1 Measurement of the levels of blood glucose
Time 0 week 4 weeks
CTL 6.26 ± 1.04 6.45 ± 0.92
DPN 19.58 ± 3.37a 20.78 ± 4.10
DPN + T1 20.95 ± 3.86a 20.58 ± 3.71
DPN + T2 19.95 ± 3.66a 20.53 ± 6.11
Note: Animals were injected subcutaneously with rhTNFR:Fc in rhTNFR:Fc-
treated groups or with physiological buffered saline (PBS) as a vehicle in
normal control (CTL) and in DPN groups twice per week for 4 weeks. Unit of
blood glucose: mmol/L. DPN, diabetic peripheral neuropathy; T1, 0.4 mg/kg
rhTNFR:Fc treatment; T2, 4 mg/kg rhTNFR:Fc treatment.
aCompared with group of CTL, P <0.05 (n = 12).
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of myelin in the TNF-α-inhibited DPN group was also im-
proved compared with the DPN group and vacuolar-like
degeneration was profoundly decreased.
Next, we stained myelin with luxol fast blue dye in
order to observe the changes and demyelination of the
myelin sheath. This specific dye can bind to myelin
imparting deep blue staining of myelin alone leaving a
clear background with unstained axona and other struc-
tures. Under an optical microscope the cross-section of
normal sciatic nerve showed central punctate appear-
ance of myelin surrounding the nerve fibers (Figure 3A),
while in longitudinal section myelin appeared as stacks
of long, neat columns surrounded by basement mem-
brane (Figure 3B). In the DPN rats the number of nerve
fibers was reduced as compared with the control rats,
depicted from both cross and longitudinal sections
(Figure 3C and 3D). The diameter of nerve fibers in
cross-section was markedly reduced suggesting the
shrinkage of nerve fibers. Axon atrophy and myelin
vacuolization was evident in the cross-sectional view of
the sciatic nerve. Longitudinal sections depicted disrup-
tion, vacuolization, and shrinkage of myelin and swelling
and atrophy of axons. An increase in Schwann cells was
also observed. The blocking of TNF-α by rhTNFR:
Fc showed marked improvement in the morphology of
sciatic nerve in DPN + T2 group compared with the DPN
group (Figure 3E and 3F). In cross section, the nerve fibers
appeared as a circular, central punctate structure
(Figure 3E).
Finally, we used transmission electron microscopy to
examine the ultrastructure of myelin. The cross-section
of sciatic nerve in normal rat presented uniform and
dense myelination with structural integrity. Lamellar
structures also showed concentric light and dark circles
and axonal shrinkage and swelling (Figure 4A and 4B).
In DPN rat model the myelin structure was disorganized
and expanded toward both the axonal and the stromal
sides (Figure 4C and 4D). There was a visible degree of
lamellar fracture, acute demyelination, and separation of
myelin sheath. Axonal microtubules and microfilaments
were disrupted and disorganized demonstrating signs of
atrophy. The ultra structure of Schwann cells showed
irregular nuclei, expanded endoplasmic reticulum,
vacuolization of mitochondria and ruptured basement
membrane. The high-dose TNF-α-inhibited DPN rats
(DPN + T2) showed dense and compact myelin struc-
ture and reduced vacuolar defects (Figure 4E and 4F).
Although some lamellar separation was still there, the
overall signs of pathology were mitigated.
Inhibition of TNF-α reversed the decrease of myelin basic
protein expression in the rats with the diabetic peripheral
neuropathy
Since MBP is critical for the myelination of nerve fibers,
next we examined the protein expression of MBP in the
sciatic nerve tissue. Compared with the control group,
DNP group showed a significant decrease in the expres-
sion of MBP (Figure 5A and 5B). The low dose inhib-
ition (0.4 mg/kg) of TNF-α in treatment group DPN +
T1 caused a slight elevation of MBP expression, whereas
the high dose inhibition (4 mg/kg) in treatment group
DPN + T2 resulted in a significant increase of MBP ex-
pression compared to the DPN group (Figure 5A; P <0.05),
reversing the DPN mediated decrease.
The MBP expression was also examined by the immu-
nohistochemistry in the sciatic nerve. The control rats
showed strong positive staining for MBP in the myelin
sheath, whereas the capillaries and axons were MBP
negative (Figure 6A). The expression of MBP in DPN
group was lower as compared with the control group
Figure 1 Diabetic peripheral neuropathy (DPN)-induced change
in motor nerve conduction velocity (MNCV) and sensory nerve
conduction velocity (SNCV). (A) Graph shows the rate of MNCV
(m/s) in different groups at day zero and week 4 post-treatment of
rhTNFR:Fc. DPN group showed significantly lower MNCV compared
with the control group. High-dose rhTNFR:Fc group (DPN + T2)
showed a significant recovery in MNCV compared with the DPN
group. (B) Graph shows the rate of SNCV (m/s) in different groups at
day zero and at week 4 post-treatment of rhTNFR:Fc. DPN group
showed significantly lower SNCV compared with the control group.
High-dose rhTNFR:Fc group (DPN + T2) showed a significant
recovery in SNCV compared with the DPN group. All measurements
were done in triplicate and data represent mean ± SEM (n = 12 per
group). Statistical significance is denoted as: * P <0.05; ** P <0.01
(4 weeks versus 0 week); a (CTL) versus b (DNP), P <0.001.
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(Figure 6B), whereas it was higher in the DPN + T2
group (Figure 6C), indicating a protective effect of
rhTNFR:Fc treatment over demyelination.
Discussion
The damage of nerves (diabetic neuropathy) occurs due
to high blood sugar levels from diabetes. About half of
the people with diabetes develop nerve damage within
10 to 20 years post diagnosis. Diabetic Peripheral Neur-
opathy is one of the most common chronic complication
of diabetes and the main reason for the disability occur-
ring in type 2 diabetes. The mechanism of the develop-
ment of DPN has not yet been fully elucidated. Previous
studies have shown that it is a multifactorial disease and
can occur due to genetic factors, hyperglycemia, abnor-
mal fat or protein metabolism, and vascular
abnormalities [12-14]. Several theories have been
established to describe the etiology of DPN, including
polyalcohol pathway, non-enzymatic protein glycosyla-
tion, abnormal lipid metabolism, oxygen-free radical
damage, and the deficiency of neurotrophic factor
[12,15]. Based on the pathogenesis, clinical treatments
include the control of blood sugar, blood pressure, blood
lipids, neurotrophic factors, antioxidants, and improve-
ment of microcirculation. However, the relief from DPN
symptoms is still not achieved. One study has shown
that, despite intensive integrated intervention with an
average follow-up of 13.3 years, there were about 55% of
diabetic patients with DPN [16]. Therefore, it has been
accepted that there must be some other factors simul-
taneously contributing to the pathology of DPN. Recent
evidence has shown the involvement of immune factors
Figure 2 Histological examination of hematoxylin and eosin (H&E) stained sciatic nerve. (A, B): Normal control; (C, D): Diabetic peripheral
neuropathy (DPN); and (E, F): High-dose rhTNFR:Fc (4 mg/kg) group (DPN + T2). Magnification: 100X (left panel, A, C, E), scale bars: 150 μm and
300X (right panel, B, D, F), scale bars: 50 μm.
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in the occurrence of DPN [17,18]. Due to differences in
genetic background, some patients may be more prone
to autoimmune disorders. Under normal circumstances,
the blood-nerve barrier functions to keep the circulating
T cells in the immune tolerance state but long-term
hyperglycemia can damage the vascular barrier of the
nerves. Myelin protein glycosylation alters its antigenic-
ity, rendering it vulnerable to the phagocytic attack of
monocytes, macrophages, and neutrophils from blood
circulation and tissue, and glial cells from nervous sys-
tem that specifically recognize the glycosylated myelin
antigen. In addition, the activated immune cells secrete
cytokines such as TNF-α, IL-1β etcetera, which impart
toxic effects on neurons and glial cells, leading to
demyelination. The stimulated monocytes and
endothelial cells have a vicious positive feed-back loop
for secretion of inflammatory substances that potenti-
ate nerve catastrophe.
Nerve biopsy in DPN patients has demonstrated that
advanced glycation end products (AGEs) are mainly
deposited in the axons and myelin sheath of nerve tissue
[19]. It has been reported that AGEs can increase
macrophage phagocytosis of nerve myelin. They execute
this effect by elevating the expression of a variety of nu-
clear factors such as NF-kB-mediated inflammatory re-
sponse genes, preventing NO-dependent vasodilatation
and anticoagulation, resulting in segmental demyelin-
ation of the nerve cells [19].
Previous studies have also shown that the expression of
TNF-α in the blood of DPN patients and rat DPN model
Figure 3 Histological examination of luxol fast blue stained sciatic nerve. (A, B): Normal control; (C, D): Diabetic peripheral neuropathy
(DPN); and (E, F): High-dose rhTNFR:Fc (4 mg/kg) group (DPN + T2). Left panel shows cross-sections with 100X amplification (A, C, E, scale
bar = 150 μm), and right panel shows longitudinal sections with 300X amplification (B, D, F, scale bar = 50 μm).
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is elevated. TNF-α is an important immune cytokine in-
volved in the developmental process of many inflamma-
tory, infectious, and autoimmune diseases and functions
to kill or inhibit tumor cells, increase the phagocytic activ-
ity of neutrophils, and stimulate the production of other
cytokines [9]. The pathological changes of DPN are char-
acterized by axonal degeneration in unmyelinated fibers,
while demyelination and diffused shrinkage in myelin
nerve fibers [20,21]. The immune response, in which self-
antigen component gets exposed, is the main reason lead-
ing to demyelination in case of DPN. T-cells activated by
these antigens produce various cytokines, including TNF-α,
which has a potential positive feed-back cycle to further
raise its own immune response to mediate the inflamma-
tory reaction [9]. It has been found that TNF-α expression
leads to the oligodendrocyte toxicity and demyelination. It
stimulates monocytes and endothelial cells to secrete IL-1β
and IL-6 and other inflammatory factors to amplify or en-
hance its effect indirectly [22]. Furthermore, TNF-α inhibits
the nitric oxide synthase (NOS) activity in vascular endo-
thelial cell, resulting in a decrease of NO-induced vasodila-
tation. It has been shown to promote the expression of
several growth factors and cell adhesion molecules,
resulting in endothelial dysfunction and pathogenesis in-
cluding stenosis, hemodynamic abnormalities, decreased
perfusion, and neurotrophic blood vessels damage [23,24].
To further confirm the role of TNF-α in the DPN
pathogenesis, in the present study, we applied subcuta-
neous injection of a TNF-α receptor-antibody fusion
protein (rhTNFR:Fc) to the DPN-induced rats in order
to inhibit TNF-α. The results showed that rhTNFR:Fc
treatment in rats with DPN significantly increased NCV
and MNCV values, particularly in high-dose group indi-
cating that rhTNFR:Fc effectively delayed the progress of
Figure 4 Transmission electron microscopy of sciatic nerve. (A, B): Normal control; (C, D): Diabetic peripheral neuropathy (DPN); and (E, F):
High-dose rhTNFR:Fc (4 mg/kg) group (DPN + T2). Left panel (A, C, E) shows 4,000X magnification (Scale bars = 5 μm) and right panel (B, D, F)
shows 13,000X magnification (Scale bars = 2 μm). Arrow indicates mitochondrion in Schwann’s cell, # key indicates the nucleus of Schwann’s cell,
triangle indicates the myelin sheath, and the star indicates the axon.
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the DPN in rats with DPN. This was further confirmed
by histological and TEM ultrastructure examination of
the sciatic nerve. The sciatic nerve of DPN-induced rats
showed the typical pathological features including thin-
ning and destruction of the myelin sheath and dis-
organization of the lamellar structures. Inhibition of
TNF-α with rhTNFR:Fc, however, resulted in a marked
improvement of sciatic nerve and its component’s
morphology. This beneficial effect of targeting TNF-α is
in agreement with a recent study that pharmacological
inhibition of TNF-α by etanercept, a TNF-α antagonist,
blocks behavioral signs of diabetic neuropathic pain [25].
Furthermore, we found an increase in MBP expression
was observed in the rhTNFR:Fc treated groups, implicat-
ing that TNF-α is the main cause of the demyelination
of the sciatic nerve. MBP is a strong basic membrane
protein produced in the oligodendrocyte cells of verte-
brate central nervous system and Schwann cells of
peripheral nervous system. It is the major constituent
protein of the nervous system myelin and is mainly lo-
calized to the myelin serosa. BMP binds to the myelin
lipids to maintain the myelin structure and functional
stability and promotes the process of myelination. When
the nerves are damaged, especially in the incidence of de-
myelination on the nerve, MBP expression is reported to
decrease in the nerves with a subsequent increase in serum
MBP levels. Currently, serum MBP is used as an indicator
of the degree of CNS and myelin damage. rhTNFR:Fc has
been applied in clinical practice in the treatment of
rheumatoid arthritis, psoriasis, and ankylosing spondylitis.
It is also reported to be useful in the treatment of various
inflammatory diseases in rat animal models [26]. Our data
supports the notion that rhTNFR:Fc may prove to be useful
for the treatment of DPN patients.
Conclusions
Thus, rhTNFR:Fc, a recombinant human type II tumor
necrosis factor receptor-antibody fusion protein, acts as
a competitor of TNF-α in the blood for binding to the
TNF-α receptor on the cell surface, thereby blocking its
activity. This study confirms that the immune cytokine
TNF-α is directly involved in the pathogenesis of DPN,
and inhibiting its activity can improve DPN symptoms
in terms of electrophysiological and morphological
changes. Our findings show that TNF-α is one of the
key mediators of the immune inflammatory response
that induces DNP and implies that rhTNFR:Fc is a
powerful candidate that should be considered for the
treatment or prevention therapy of DPN. The specific
mechanism of immune damage on DPN, however, still
requires further study to develop reliable therapeutic
strategies and alleviate the potential of DPN disorder
particularly in patients suffering from diabetes.
Figure 5 Rescue of myelin basic protein (MBP) expression in
diabetes peripheral neuropathy (DPN)-induced rats treated
with rhTNFR:Fc. Total protein was extracted and equal amount of
protein from different samples was subjected to SDS-PAGE. Physiological
buffered saline was used as a vehicle in normal control and DPN groups.
DPN + T1, DNP plus low dose of rhTNFR:Fc (0.4 mg/kg); DPN + T2, DNP
plus high dose of rhTNFR:Fc group (4 mg/kg). (A) Quantitative analysis,
using densitometry of western blot from three independent experiments
is shown. The expression of MBP was normalized to β-actin. Data
represents mean ± SEM. Different letters denote significance, P <0.05,
n = 12 experiments. (B) Representative western blot is shown.
Figure 6 Expression of myelin basic protein (MBP) by Immunohistochemistry. Immunohistochemical staining of MBP in sciatic nerve.
(A) Normal control; (B) Diabetic peripheral neuropathy (DPN); C) DPN + T2. Magnification = 300X, scale bars = 50 μm.
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